Penn LDI’s Eric Roberts Wins AcademyHealth Publication of the Year Award
Cited for the “Most Outstanding” Health Services Research of 2025
Improving Care for Older Adults
In Their Own Words
Lessons from Landmark Drug Revolutions for the Future of Alzheimer’s Treatment
An LDI Fellow Draws on Historic, Paradigm-Shifting Treatments in Depression and Obesity to Consider What Meaningful Breakthroughs in Dementia Care Could Look Like
Print:
This essay originally appeared in STAT News on December 22, 2025 as part of the Neurotransmissions column.
In the weeks leading up to Dec. 3, I imagined a fantastic headline: “Ozempic treats Alzheimer’s disease.”
On that day, at the CtAD 2025 meeting (CtAD stands for Clinical Trials in Alzheimer’s Disease), in the Sapphire Ballroom of the Hilton San Diego Bayfront hotel, Novo Nordisk would present to the assembly of scientists and biopharma executives the results of its EVOKE studies, two clinical trials testing whether semaglutide can treat people with early-stage symptomatic Alzheimer’s disease. Semaglutide is, of course, the chemical name for the brand Ozempic, FDA labeled for the treatment of diabetes and to reduce the risk of major cardiovascular events, but widely known as a drug for obesity.
Read the full essay here.
Author
Jason Karlawish, MD
Professor, Medicine and Professor, Medical Ethics and Health Policy, Perelman School of Medicine; Co-Director, Penn Memory Center
More on Improving Care for Older Adults
America’s Caregiver Crisis is Burning Out Millions of Families
Coaching and Support Can Help But Are Rarely Used, LDI Experts Say
Can Washington State Lead the Way on Long-Term Care Financing?
WA Cares Can Offer a Potential Blueprint for Public Long-Term Care Financing Nationwide
PARC Retreat Explores How Aging, Workforce Strains, and Federal Debt Are Reshaping U.S. Health Care
Penn Gathering of Experts Examines the Growing Pressures Facing Older Americans
A Simple, Gamified Program Boosted Walking in Parkinson’s Patients
Chart of the Day: Remote Intervention with Gaming Elements Shows Promise, LDI Expert Finds
Medicare Advantage ‘Working’ for Seniors, but Not for Taxpayers, Experts Say
Penn LDI Panel Cites Costs for Enrollees Alongside Billions in Overpayments and Systemic Gaming